Devices/Safety Alert·openFDA/device

SURGUARD2 SAFETY HYPODERMIC NEEDLE (TERUMO PHILIPPINES CORPORATION) — Malfunction

MediumPublished Jun 30, 2026· AI-analyzed Jul 14, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

A malfunction was reported involving the SurGuard2 Safety Hypodermic Needle manufactured by Terumo Philippines Corporation. The source documents the event under a malfunction classification without specifying the technical failure mode.

Who it affects

This notice affects Terumo Philippines Corporation and stakeholders involved in the supply chain, clinical use, and quality monitoring of the SurGuard2 safety needle product line.

Why it matters

Reporting of a malfunction for a safety-engineered device suggests a potential failure in the mechanism designed to prevent needlestick injuries. For regulatory professionals, this indicates a need to monitor for potential shifts in the device's benefit-risk profile or a possible increase in MDR (Medical Device Reporting) frequency for this specific product code.

Practical takeaway

Regulatory and quality teams should review recent complaint logs for the SurGuard2 line to determine if this malfunction aligns with known failure modes or represents a new trend necessitating CAPA initiation. Manufacturing units may need to verify needle-to-hub bonding and safety mechanism integrity during upcoming routine inspections.

FDA source material

Event type: Malfunction. Device: SURGUARD2 SAFETY HYPODERMIC NEEDLE by TERUMO PHILIPPINES CORPORATION.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.